765 related articles for article (PubMed ID: 16337092)
41. Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.
Kurkowska-Jastrzebska I; Bałkowiec-Iskra E; Ciesielska A; Joniec I; Cudna A; Zaremba MM; Członkowski A; Członkowska A
Int Immunopharmacol; 2009 Jun; 9(6):781-91. PubMed ID: 19286483
[TBL] [Abstract][Full Text] [Related]
42. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action.
Kim YJ; Park HJ; Lee G; Bang OY; Ahn YH; Joe E; Kim HO; Lee PH
Glia; 2009 Jan; 57(1):13-23. PubMed ID: 18661552
[TBL] [Abstract][Full Text] [Related]
43. Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-κB-dependent inflammation process in a mouse model of Parkinson's disease.
Anitua E; Pascual C; Pérez-Gonzalez R; Orive G; Carro E
J Control Release; 2015 Apr; 203():170-80. PubMed ID: 25702964
[TBL] [Abstract][Full Text] [Related]
44. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity.
McLaughlin P; Zhou Y; Ma T; Liu J; Zhang W; Hong JS; Kovacs M; Zhang J
Glia; 2006 Apr; 53(6):567-82. PubMed ID: 16419087
[TBL] [Abstract][Full Text] [Related]
45. Minor retinal degeneration in Parkinson's disease.
Huang YM; Yin ZQ
Med Hypotheses; 2011 Feb; 76(2):194-6. PubMed ID: 20933338
[TBL] [Abstract][Full Text] [Related]
46. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
47. Pathogenesis and animal studies of Parkinson's disease.
Oertel WH; Kupsch A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
[TBL] [Abstract][Full Text] [Related]
48. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
[TBL] [Abstract][Full Text] [Related]
49. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
Tsai SJ
Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
[TBL] [Abstract][Full Text] [Related]
50. MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats.
Wang WF; Wu SL; Liou YM; Wang AL; Pawlak CR; Ho YJ
Behav Neurosci; 2009 Dec; 123(6):1261-70. PubMed ID: 20001109
[TBL] [Abstract][Full Text] [Related]
51. Experimental models of Parkinson's disease: insights from many models.
Tolwani RJ; Jakowec MW; Petzinger GM; Green S; Waggie K
Lab Anim Sci; 1999 Aug; 49(4):363-71. PubMed ID: 10480640
[TBL] [Abstract][Full Text] [Related]
52. Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X
Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563
[TBL] [Abstract][Full Text] [Related]
53. Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra.
Dietz GP; Stockhausen KV; Dietz B; Falkenburger BH; Valbuena P; Opazo F; Lingor P; Meuer K; Weishaupt JH; Schulz JB; Bähr M
J Neurochem; 2008 Feb; 104(3):757-65. PubMed ID: 17995935
[TBL] [Abstract][Full Text] [Related]
54. Neural degeneration and the transport of neurotransmitters.
Edwards RH
Ann Neurol; 1993 Nov; 34(5):638-45. PubMed ID: 7902065
[TBL] [Abstract][Full Text] [Related]
55. Neuroprotective actions of sex steroids in Parkinson's disease.
Bourque M; Dluzen DE; Di Paolo T
Front Neuroendocrinol; 2009 Jul; 30(2):142-57. PubMed ID: 19410597
[TBL] [Abstract][Full Text] [Related]
56. Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson's disease: focus on endogenous neurorestoration.
'Episcopo FL; Tirolo C; Testa N; Caniglia S; Morale MC; Marchetti B
Curr Aging Sci; 2013 Feb; 6(1):45-55. PubMed ID: 23895521
[TBL] [Abstract][Full Text] [Related]
57. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL
Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218
[TBL] [Abstract][Full Text] [Related]
58. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
59. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens.
Gillies GE; McArthur S
Horm Behav; 2010 Jan; 57(1):23-34. PubMed ID: 19538962
[TBL] [Abstract][Full Text] [Related]
60. Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinson's disease.
Kurkowska-Jastrzebska I; Bałkowiec-Iskra E; Joniec I; Litwin T; Członkowski A; Członkowska A
Neuroscience; 2005; 131(1):247-54. PubMed ID: 15680707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
